- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05887791
Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects
January 5, 2024 updated by: Rousselot BVBA
Clinical Study to Assess the Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects: Randomized, Double-blind, Placebo-controlled, Cross-over Study With Different Dosages
To investigate the effect of two different dosages collagen hydrolysate (CH) on postprandial blood glucose and insulin profile in prediabetic and normo-glycaemic subjects.This will be investigated in a cross-over randomized double-blind placebo controlled study design.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Esslingen, Germany, 73728
- BioTeSys GmbH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Main Inclusion Criteria:
- Prediabetic subjects: Male and female subjects with prediabetic HbA1c values between 5.7% and 6.4% and/or fasting glucose ≥ 100 mg/dL and ≤ 125 mg/dL (in venous plasma) (twice confirmed at two independent days if HbA1c is < 5.7%) or Healthy normo-glycaemic subjects: fasting glucose <100 mg/dL and HbA1c is < 5.7%
- Age: 18-70 years
- Body mass index 19-35 kg/m2
- Current Non-smoker
- Signed informed consent form
- No changes in food habits or physical activity 3 months prior to screening and during the study
- If applicable, stable intake of chronic medication of at least 4 weeks
Main Exclusion Criteria:
- Subjects with diagnosed Type 2 Diabetes mellitus with medical treatment
- Presence of disease or drug(s) influencing digestion (incl. recent intake of antibiotics) and absorption of nutrients
- Intake of medications known to affect glucose tolerance, e.g., diabetic medication, SGLT-2 inhibitors, GLP-1 receptor agonists, steroids, protease inhibitors or antipsychotics
- Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the Investigator's opinion would impact patient safety
- Severe liver or renal disease or laboratory evidence of hepatic dysfunction (i.e. alkaline phosphatase, ALT, AST >3 x ULN)
- Known inflammatory or malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer, pancreatitis)
- Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs
- Intake of food supplements known to affect glucose tolerance, e.g., cinnamon capsules, conjugated linoleic acids
- Drug-, alcohol- and medication abuses
- Pregnant or breast-feeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Collagen hydrolysate dose 1
Source: porcine; standardized to 10 g provided as single dose.
Orally applied in flavoured water.
|
Single dose
|
Experimental: Collagen hydrolysate dose 2
Source: porcine; standardized to 5 g provided as single dose.
Orally applied in flavoured water.
|
Single dose
|
Placebo Comparator: Placebo
Flavoured water
|
Single dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose iAUC
Time Frame: 0-180 minutes postprandially
|
Area under the curve (AUC) calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-180minutes)
|
0-180 minutes postprandially
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose iAUC
Time Frame: 0-240 minutes postprandially
|
Area under the curve calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-240minutes)
|
0-240 minutes postprandially
|
Glucose Cmax
Time Frame: 0-180 minutes postprandially
|
Maximum blood glucose concentration (Cmax)
|
0-180 minutes postprandially
|
Delta Cmax
Time Frame: 0-180 minutes postprandially
|
Maximum increase of blood glucose concentration
|
0-180 minutes postprandially
|
Tmax
Time Frame: 0-180 minutes postprandially
|
Time to reach maximum blood glucose concentration (Tmax)
|
0-180 minutes postprandially
|
T baseline
Time Frame: 0-240 minutes postprandially
|
First time to reach baseline again after increase or decrease in blood glucose
|
0-240 minutes postprandially
|
Matsuda-Index
Time Frame: 0-120 minutes postprandially
|
Determination of Insulin sensitivity
|
0-120 minutes postprandially
|
Glucose dip
Time Frame: 0-240 minutes postprandially
|
maximum dip below baseline and time point of glucose dip
|
0-240 minutes postprandially
|
Insulin iAUC
Time Frame: up to 0-240 minutes postprandially
|
Area under the curve calculated as the incremental area under the insulin curve
|
up to 0-240 minutes postprandially
|
GLP-1
Time Frame: 0-120 minutes postprandially
|
Incretin response (Glucagon-like Peptide-1)
|
0-120 minutes postprandially
|
Satiety assessment
Time Frame: 0-240 minutes postprandially
|
Visual analog scale (VAS) Scale (0: not at all 100: extremely)
|
0-240 minutes postprandially
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastrointestinal hormones
Time Frame: 0-120 minutes postprandially
|
Peptid YY (PYY), Ghrelin, Cholecystokinin (CCK), Leptin
|
0-120 minutes postprandially
|
Amino acids
Time Frame: 0-240 minutes postprandially
|
Concentration-time curve of amino acids in plasma together with small molecular weight peptides
|
0-240 minutes postprandially
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Nicoletta Virgilio, PhD, Rousselot BV
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 15, 2023
Primary Completion (Actual)
December 23, 2023
Study Completion (Estimated)
April 23, 2024
Study Registration Dates
First Submitted
May 24, 2023
First Submitted That Met QC Criteria
May 24, 2023
First Posted (Actual)
June 5, 2023
Study Record Updates
Last Update Posted (Estimated)
January 8, 2024
Last Update Submitted That Met QC Criteria
January 5, 2024
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTS1984/23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States